Avatar

Swaraj Paul Barooah

.

Others

Youth Workshop on IP, Public Health and Access to Medicines

by
Leave a Comment

The 4th Global Congress on Intellectual Property and the Public Interest, scheduled to be held from 15-17th December, 2015 at National Law University, Delhi is fast approaching. Interested candidates who haven’t yet sent in their applications to participate are encouraged to do so at the earliest. To coincide with the 4th Global Congress on Intellectual Property and Public Interest, ISID, PHM and Prayas are conducting a four-day post-congress youth workshop on intellectual property, public health and access to medicines. Selected participants will:…


Read More »
Drug Regulation Innovation Patent

The good that Martin Shkreli has done

by
1 Comment

As many of our readers may have heard by now, Martin Shkreli, ex-hedge fund manager and current founder and CEO of Turing Pharmaceuticals is currently in the eye of a torrid storm of anger after he increased the price of Daraprim overnight from $13.50 per pill to $750 per pill. This 5500% increase came within 2 months of acquiring the rights to the drug from Impax laboratories. Daraprim is a treatment for toxoplasmosis, which affects people whose immune systems have been weakened by chemotherapy,…


Read More »
Patent

New CRI Guidelines seem to be result of Patent Office Overreach

by
4 Comments

Troubling times lie ahead for the Indian IT sector as the recently released Guidelines for Examination of Computer Related Inventions seem to have opened the backdoor to software patenting. While the intention of the Patent Office in releasing these Guidelines may have simply been to help foster some clarity and uniformity in patent office practice, the language of the Guidelines paves the way for some unexpected policy changes. Several policy think tanks including iSpirt, Software Freedom Law Centre, Centre for Internet and Society, etc have expressed…


Read More »
Innovation

Global Innovation Index 2015: Looking at India’s performance

by
2 Comments

The Global Innovation Index (GII) 2015, released yesterday, saw India ranked a disappointing 81 out of the 141 countries surveyed. Topping the list for the 5th year running is Switzerland, followed by UK and Sweden. The GII, currently in its 8th edition, is an annual report co-published by Cornell University, INSEAD, and the World Intellectual Property Organization (WIPO). Using 79 indicators from over 30 international sources, and with a transparent and replicable computation methodology, it is widely recognized as the…


Read More »
Others

SpicyIP – Call for bloggers!

by
6 Comments

2015 marks the completion of ten years since we started out our journey to promote awareness about intellectual property issues in India. These years have been exciting, enriching and have given us the opportunity to learn from all our readers as well as add our bit towards discussing the issues that were of concern to us. To continue this process of collaborative learning, Spicy IP is extremely pleased to announce that we are keen to infuse our team with new blood….


Read More »
Patent

Guest Post: Symed’s Linezolid patent case – A response

by
Leave a Comment

A couple of weeks ago, Rupali carried a piece on the blog titled “‘Glenmark process’ does not violate Symed’s linezolid patent: DHC“. Shortly after, we received an email from Symed stating that the post did not accurately convey the situation at hand. Both the author and I looked over the post and did not see anything amiss, and went on to make some minor clarificatory edits. At this point, I should admit that though I should have, I did not follow up with…


Read More »
Others

Breaking News: IPAB SLP Dismissed!

by
Leave a Comment

[Posted on behalf of Prof. Shamnad Basheer, as taken from his email sent out to the SpicyIP subscriber list earlier today]:  In a significant development for Indian IP law, the Supreme Court (a bench consisting of Justices Gogoi and Ramanna) dismissed the government’s appeal in our IPAB PIL matter. With this dismissal, the earlier Madras High Court ruling striking down key provisions of the IPAB as unconstitutional has attained finality. By way of background, I had filed a PIL (public interest…


Read More »
Traditional Knowledge

Guest Post: Safeguarding the Sacredness of Traditional Knowledge – an Argument for a Sui Generis Framework for its Protection

by
3 Comments

With the current debates and discussions going on around Traditional Knowledge (for e.g., see Praveen Raj’s guest post here, or IPKat’s recent post here) we’re happy to bring our readers a sharp guest post by Rahul Bajaj looking into the intricacies of how a sui generis framework for TK could/should work. Rahul Bajaj is a 4th year law student from Nagpur and is passionate about constitutional law, intellectual property law, cyber law and disability law. He is particularly interested in studying the…


Read More »
Others

Guest Post: gTLD fun .sucks me not

by
2 Comments

We’re happy to bring our readers a very interesting guest post by Santosh Vikram Singh on what could turn out to be a huge cyber-squatting issue – it turns out that there is a recently launched gTLD (such as “.com”, or “.org”, etc) which may be uniquely situated to bring together criticism/trolling over any topic, company or person! A fascinating issue which may be especially relevant to big brands and celebrities of all varieties, do read on for more. Santosh is a…


Read More »
Patent

US, Switzerland take out WTO gun for India’s Sec 3(d); point at foot

by
Leave a Comment

In yet another “Indian Pharma Patent Policy” centric international development, an article from LiveMint (view here), reports that India’s Section 3(d) may be facing pressure from a relatively unexplored angle. According to the article, US and Switzerland may be coming up with a creative approach to bring India to the WTO dispute settlement system. Up till now, despite all the pressure by US, India’s pharmaceutical patent provisions had not been challenged at the WTO arena, presumably because any such challenge would be a…


Read More »
  1. Pages:
  3. 1
  4. 2
  5. 3
  6. 4
  7. 5
  8. 6
  9. 7
  10. 8
  11. 9
  12. ...
  13. 40